Skip to main content
MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED logo

MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · MVP ISIN · AU000000MVP2 LEI · 9845007EAECAOD1U4493 ASX Manufacturing
Open in API
Filings indexed 908 across all filing types
Latest filing 2018-04-09 Regulatory Filings
Country AU Australia
Listing ASX MVP

About MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

https://medicaldev.com

Medical Developments International Limited specializes in the development and distribution of emergency pain relief and respiratory products. The company's flagship product is Penthrox, a handheld, self-administered inhaler providing rapid-onset, non-opioid analgesia using methoxyflurane. Penthrox is utilized globally by emergency medical services, hospitals, and for procedural pain in various clinical settings. Additionally, the company manufactures a range of respiratory medical devices, including anti-static spacers and asthma management tools designed to optimize medication delivery. The organization focuses on providing portable, effective solutions for acute pain management and respiratory care, catering to healthcare professionals and patients in emergency, surgical, and primary care environments.

Recent filings

Filing Released Lang Actions
Penthrox is approved in Canada 2 pages 116.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 10 April 2018 about the approval of the product PENTHROX in Canada. It contains no financial statements, no regulatory filings, no voting results, no management changes, no earnings data, or other report types. It is a corporate announcement about product approval and partnership details. The document length is 5577 characters, which is relatively short and the content is clearly an announcement rather than a report or detailed financial disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for general regulatory announcements and miscellaneous filings that do not fit other specific categories.
2018-04-09 English
Penthrox approved in Germany 3 pages 308.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 5 April 2018 about the approval of the product Penthrox in Germany. It contains no financial data, no mention of financial results, no regulatory filings, no voting results, no management changes, no legal proceedings, no capital changes, and no detailed report content. The document is relatively short (4045 characters) and reads as a news announcement about product approval and market expansion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or any detailed financial or governance report. It is a general regulatory announcement about product approval and market status, which fits best under Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2018-04-04 English
Penthrox approved in Sweden, Norway, Poland and Croatia 2 pages 452.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 27 March 2018 about the approval of the product Penthrox in several European countries. It contains no financial statements, no management discussion of financial results, no regulatory certifications, or voting results. The content is a straightforward announcement of product approval and market expansion. The document length is 3357 characters, which is relatively short and typical for a regulatory announcement rather than a full report. There is no indication that this is a report publication announcement or a certification. The content does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is a regulatory announcement about product approval, which fits best under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2018-03-26 English
Appendix 3B 12 pages 691.7KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class and number of securities issued, issue price, purpose of the issue, and compliance with ASX listing rules. It includes calculations of placement capacity under ASX rules 7.1 and 7.1A, which relate to the company's ability to issue new shares without shareholder approval. The document is a formal announcement to the Australian Securities Exchange (ASX) regarding a new issue of securities and application for quotation of additional securities. It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about capital raising and securities issuance. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP). The document length (15,000 characters) and content confirm it is a full announcement, not just a brief notice or report publication announcement.
2018-03-26 English
Global demand for Medical Developments Shares 2 pages 250.9KB
Director's Dealing Classification · 100% confidence The document is an ASX announcement dated 20 March 2018 regarding the sale of shares by the Chairman of Medical Developments International Ltd. It details the off-market sale of 5 million shares by the Chairman and discusses investor interest and shareholder base expansion. There is no financial report, earnings data, or detailed financial analysis. The document is short (3041 characters) and focuses on a director's personal share transaction. This fits the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives (insider trades).
2018-03-19 English
Change of Director's Interest Notice 2 pages 250.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including the number of shares disposed and held before and after the change. The document is a formal notification of a director's personal share transactions, specifically an off-market trade of shares. There is no financial performance data, earnings information, or report publication content. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 3588 characters, which is consistent with a detailed notice but not a full report. Therefore, the correct classification is DIRS with high confidence.
2018-03-19 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.